文献速递类风湿关节炎

难治性类风湿关节炎患者的五年随访

Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本研究对2018年识别的难治性类风湿关节炎(D2T RA)患者随访至2023年,分析其长期结局。150例纳入分析中,67例(45%)D2T RA缓解,75例(50%)持续为D2T RA,8例(5%)死亡。多药耐药患者中38%缓解,主要经治疗调整。风湿病合并症指数和糖皮质激素剂量增加是死亡的独立危险因素。

要点

  • 五年随访中45%的D2T RA患者缓解,50%持续难治,5%死亡。
  • 缓解者更年轻、治疗变更比例更高、2023年IL-6受体抑制剂使用比例更高。
  • 风湿病合并症指数(OR 3.50)和糖皮质激素剂量增加(OR 31.9)是死亡的独立危险因素。

核心结论

  • 进一步调整RA治疗有助于缓解D2T RA。
  • 多重合并症和糖皮质激素使用与死亡相关。

研究设计与样本

  • 收集2018年识别为D2T RA的患者至2023年的临床病程数据。
  • 根据末次访视结局将患者分为缓解D2T RA、持续D2T RA和死亡三组。
  • 比较各组临床特征,并探究D2T RA缓解或死亡的预测因素。
  • 分析2018年确定的D2T RA原因、多药耐药、合并症和社会经济因素对2023年结局的影响。
  • 2018年识别173例D2T RA患者,150例纳入分析。

主要发现

  • 150例中,D2T RA缓解67例(45%),持续D2T RA 75例(50%),死亡8例(5%)。
  • 与持续D2T RA或死亡患者相比,缓解D2T RA患者末次访视时显著更年轻(P = 0.02)。
  • 缓解D2T RA患者五年内治疗变更比例更高(P = 0.002)。
  • 缓解D2T RA患者2023年IL-6受体抑制剂使用比例更高(P = 0.04)。
  • 多药耐药患者中38% D2T RA缓解,主要经治疗变更实现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To elucidate the long-term outcomes of patients with difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: We collected data on the clinical course of patients who had been identified as D2T RA in 2018 until 2023. We stratified the patients according to outcomes at the last visit: resolved D2T RA, persistent D2T RA and mortality. We compared their clinical characteristics and investigated the predictive factors for the resolution of D2T RA or mortality. Furthermore, we investigated the impact of the causes of D2T RA identified in 2018, multidrug resistance, comorbidities and socioeconomic factors on outcomes in 2023. RESULTS: Of 173 patients identified as D2T RA in 2018, 150 were included in the analysis. Among them, D2T RA was resolved in 67 (45%), 75 (50%) remained as D2T RA, and 8 (5%) died. Patients with resolved D2T RA were significantly younger at the latest visit (P = 0.02), had a higher proportion of treatment changes during five years (P = 0.002), and had a higher proportion of interleukin-6 receptor inhibitors use in 2023 (P = 0.04) than those in patients with persistent D2T RA or those who died. D2T RA resolved in 38% of patients with multidrug resistance, mainly with treatment changes. Rheumatic disease comorbidity index and glucocorticoid dose escalation were independent risk factors for mortality [odds ratio (OR), 3.50; P = 0.02 and OR, 31.9; P = 0.002, respectively]. CONCLUSION: Further modifications in RA treatment are useful for resolving D2T RA. Multiple comorbidities and glucocorticoid use are associated with mortality.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Takanashi S, Takeuchi T, Kaneko Y, et al. Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 38851883. doi:10.1093/rheumatology/keae325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。